8-K: Chrome Holding Co. Files September Operating Report Amid Chapter 11

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its September 2025 monthly operating report, detailing financial status and ongoing Chapter 11 proceedings, including asset sales and plan confirmation efforts.

Summary

• Filed its monthly operating report for the period ended September 30, 2025, as part of its ongoing Chapter 11 bankruptcy cases.
• The company has been operating under Chapter 11 bankruptcy protection since March 23, 2025.
• The Second Amended Joint Chapter 11 Plan and Disclosure Statement were filed on September 24, 2025, with a confirmation hearing scheduled for November 19, 2025.
• Substantially all of the Debtors' assets were sold to 23andMe Research Institute on July 14, 2025, and the $35 million Debtor-in-Possession (DIP) financing facility was repaid on the same date.
• A Stock Purchase Agreement for the Lemonaid telehealth business was entered into on September 10, 2025, which remains subject to Court approval through the Debtors' Plan.
• Reported a consolidated net loss of $1,405 thousand for the month of September 2025.
• The cash balance at the end of September 2025 was $271,683 thousand, including $25.5 million in Professional Fee Admin Reserves.

Sentiment

Score: 2

Explanation: The company is in Chapter 11 bankruptcy, and while it has made progress in its proceedings and asset sales, the explicit warnings about the speculative nature of its common stock and the unlikelihood of recovery for equity holders indicate a very negative outlook for investors. The ongoing net loss further reinforces this negative sentiment.

Positives

• Successful sale of substantially all assets to 23andMe Research Institute on July 14, 2025, generating a gain of $7,648 thousand on the sale of a subsidiary.
• Repayment of the $35 million Debtor-in-Possession (DIP) financing facility on July 14, 2025, indicating improved liquidity or asset monetization.
• Maintained a significant cash balance of $271,683 thousand as of September 30, 2025, which includes $25.5 million designated for Professional Fee Admin Reserves.
• Progress in the Chapter 11 proceedings with the filing of the Second Amended Joint Chapter 11 Plan and Disclosure Statement, and the scheduling of a confirmation hearing.
• Entry into a Stock Purchase Agreement for the Lemonaid telehealth business, signaling further asset monetization and a path towards resolution.

Negatives

• The company is currently operating under Chapter 11 bankruptcy protection, having filed voluntary petitions on March 23, 2025.
• Trading in the company's Class A common stock is explicitly stated to be highly speculative and poses substantial risks, with prices potentially bearing little or no relationship to actual recovery for shareholders.
• The Monthly Operating Report is unaudited, not prepared in accordance with Generally Accepted Accounting Principles (GAAP), limited in scope, and subject to material future adjustments and reconciliation.
• Reported a consolidated net loss of $1,405 thousand for the month of September 2025.
• Significant legal and professional fees totaling $5,691 thousand ($386k professional fees + $5,220k legal fees + $85k board fees) were recognized in the income statement for the reporting period.
• The company has a substantial accumulated deficit of $(2,149,996) thousand from net income and $(67,064) thousand from retained earnings.

Risks

• Risks and uncertainties relating to the Chapter 11 Cases, including obtaining Court approval for motions, the effects on the Company and its constituents, Court rulings, and the general outcome of the cases.
• Uncertainty regarding whether the relevant proposed plan or any amendments will be confirmed by the Court and whether the effective date of such plan occurs.
• The length of time the Company will operate under the Chapter 11 Cases.
• Risks associated with any third-party motions in the Chapter 11 Cases.
• Adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Chapter 11 Cases.
• Trading in the Company's Class A common stock is highly speculative and poses substantial risks, with trading prices potentially bearing little or no relationship to the actual recovery, if any, by holders of the Common Stock.
• No assurance of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares.
• The financial information contained in the Monthly Operating Report is unaudited, not prepared in accordance with GAAP, limited in scope, and subject to future adjustment and reconciliation, with potential for material changes.
• Forward-looking statements involve a number of risks, uncertainties, or other assumptions that may cause actual results or performance to differ materially from those expressed or implied.

Future Outlook

The company will continue to file monthly operating reports with the Court during the pendency of the Chapter 11 Cases. A hearing to consider confirmation of the Second Amended Joint Chapter 11 Plan is scheduled for November 19, 2025. The sale of the Lemonaid telehealth business remains subject to Court approval through the Debtors' Plan.

Management Comments

• "Trading in the Company's Class A common stock... during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks."
• "Trading prices for the Company's Common Stock may bear little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases."
• "The Company cannot assure investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares of the Common Stock."
• "The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Report, which was not prepared for the purpose of providing the basis for an investment decision."
• "The Debtors believe that the financial information may be subject to change, and these changes could be material."
• "There can be no assurance that, from the perspective of an investor or potential investor in the Company's securities, the Monthly Operating Report is complete."
• "Results and projections set forth in the Monthly Operating Report should not be viewed as indicative of future results."

Industry Context

This filing reflects a company undergoing significant restructuring within the biotech and telehealth sectors. The divestment of 'substantially all assets' and the Lemonaid telehealth business indicates a strategic liquidation or streamlining of operations to address financial distress. The ongoing Chapter 11 proceedings highlight the severe financial challenges, which are not uncommon in highly competitive or rapidly evolving industries where business models may struggle to achieve profitability or face intense market pressures. The explicit cautionary notes regarding common stock trading are typical for companies in bankruptcy, underscoring the high risk for equity holders in such situations.

Comparison to Industry Standards

• The company's current financial state, operating under Chapter 11 bankruptcy, is significantly below industry standards for healthy, publicly traded companies in the biotech and telehealth sectors.
• The sale of 'substantially all assets' and the Lemonaid telehealth business represents a distressed asset sale, which contrasts sharply with the growth-oriented mergers and acquisitions or strategic expansions typically pursued by thriving industry players like Teladoc Health or Amwell.
• The reported consolidated net loss of $1,405 thousand for September 2025, even after major asset sales, indicates continued operational challenges, diverging from the profitability or strong revenue growth seen in successful industry peers.
• The explicit warnings about the highly speculative nature of the common stock and the unlikelihood of recovery for equity holders are a stark contrast to the investment profiles of stable or growing companies within the biotech and telehealth industries.

Corporate Governance

Legal Proceedings

• Ongoing Chapter 11 bankruptcy cases (Case No. 25-40976-357) in the United States Bankruptcy Court for the Eastern District of Missouri, jointly administered.
• Court orders related to joint administration, Debtor-in-Possession (DIP) financing, asset sales, and plan confirmation.
• Ancillary proceedings in the Supreme Court of British Columbia in Vancouver, British Columbia, under the Companies Creditors Arrangement Act, where Matthew Kvarda acts as Foreign Representative.

Related Party Transactions

• Sale of substantially all of the Debtors' assets to 23andMe Research Institute f/k/a TTAM Research Institute. Given the company's former name (23andMe Holding Co.), this entity is highly likely to be a related party.

Stakeholder Impact

• **Shareholders**: Face substantial risks, with management explicitly stating that common stock trading is highly speculative and may bear little or no relationship to actual recovery, implying a high probability of significant loss of investment.
• **Creditors**: Unsecured creditors are represented by an official committee, and a plan of reorganization has been filed to address their claims. The DIP lender has been fully repaid.
• **Employees**: The Monthly Operating Report indicates 0 full-time employees, suggesting a significant impact on the workforce due to the bankruptcy and asset sales.
• **Customers**: The sale of the Lemonaid telehealth business suggests continuity of services under a new owner, but the overall impact on customer experience from the bankruptcy is not detailed.
• **Suppliers**: Payments on prepetition claims are subject to the bankruptcy process, potentially impacting suppliers who are owed money from before the petition date.

Next Steps

• Continue filing monthly operating reports with the U.S. Bankruptcy Court for the Eastern District of Missouri.
• Attend the confirmation hearing for the Second Amended Joint Chapter 11 Plan scheduled for November 19, 2025.
• Address any objections to the Plan confirmation, with a deadline of November 6, 2025.
• Seek Court approval for the sale of the Lemonaid telehealth business through the Debtors' Plan.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, and management has explicitly warned that trading in its common stock is 'highly speculative and poses substantial risks,' with prices potentially bearing 'little or no relationship to the actual recovery, if any, by holders of the Common Stock.' This indicates a near-total loss for equity holders is highly probable. Despite progress in asset sales and plan confirmation, the fundamental outlook for existing shareholders is extremely negative, making a 'strong sell' recommendation appropriate for any remaining holdings.

Keywords

Chapter 11, Bankruptcy, SEC Filing, Monthly Operating Report, Asset Sale, DIP Financing, Telehealth, 23andMe, Chrome Holding Co., Corporate Restructuring, Financial Reporting, Creditors Committee, Equity Committee, Plan Confirmation